VERTEX PHARMACEUTICALS INC / MA Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 20.08 thousand shares for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-10.
Discontinued › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2023-02-10
- VERTEX PHARMACEUTICALS INC / MA share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2022 was 20.08K shares, a 26.46% decline from fiscal 2021.
- VERTEX PHARMACEUTICALS INC / MA share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2021 was 27.30K shares, a 20.61% increase from fiscal 2020.
- VERTEX PHARMACEUTICALS INC / MA share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2020 was 22.64K shares, a 98.51% decline from fiscal 2019.
- VERTEX PHARMACEUTICALS INC / MA share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2019 was 1.52M shares, a 33.80% decline from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month as first filed |
|---|---|---|
| 2022-12-31 | 20.08K shares 10-K · filed 2023-02-10 | |
| 2021-12-31 | 27.30K shares 10-K · filed 2023-02-10 | |
| 2020-12-31 | 22.64K shares 10-K · filed 2023-02-10 | |
| 2019-12-31 | 1.52M shares 10-K · filed 2022-02-09 | 1.52M shares 10-K · filed 2020-02-13 |
| 2018-12-31 | 2.30M shares 10-K · filed 2021-02-11 | 2.30M shares 10-K · filed 2019-02-13 |
| 2017-12-31 | 2.36M shares 10-K · filed 2018-02-15 | |
| 2016-12-31 | 3.18M shares 10-K · filed 2017-02-23 | |
| 2015-12-31 | 3.53M shares 10-K · filed 2016-02-16 | |
| 2014-12-31 | 3.61M shares 10-K · filed 2015-02-13 | |
| 2013-12-31 | 4.84M shares 10-K · filed 2014-02-11 | |
| 2012-12-31 | 6.04M shares 10-K · filed 2013-03-01 | |
| 2010-12-31 | 4.62M shares 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |